The FDA warned Boston Scientific that quality control problems at six of its manufacturing facilities still need to be addressed. The FDA warned the company has not fixed "continuing serious deficiencies." In the worst case scenario, the warning could mean that the device maker might be prevented from introducing new products until changes are made to correct the problems. The warning came only hours after Boston Scientific closed its $27.2 billion merger with Guidant on Tuesday. Some analysts think the news could impact the transaction, noting that a drop in the price of Boston Scientific's shares might affect the company's ability to close the deal.
- see this article from The Boston Globe
ALSO: A look at just how bad things were over the last quarter at Guidant after its recalls: Defibrillator sales were down 19 percent, and pacemakers were down 24 percent. Article